Fosun Xingmai Secures Over RMB 100 Million in Strategic Financing, Gaining Strong Capital Market Recognition for Its Multi-Product AI Medical Imaging Matrix

On July 29, Shanghai Aitrox Technology Co., Ltd. (hereinafter referred to as “FUSUN AITROX”) completed a strategic financing round exceeding RMB 100 million, jointly led by Fosun Pharma and Sinopharm China International Capital, with Anting Industrial participating as a follow-on investor. Existing shareholder Fosun Pharma increased its investment in this round, demonstrating strong confidence in FUSUN AITROX, while also introducing industrial capital partners to jointly support the company’s rapid growth.

According to industry research reports, the market size of China's medical artificial intelligence (AI) sector is maintaining rapid growth and is projected to exceed RMB 100 billion by 2030. As the demand for precision medicine continues to expand, placing higher requirements on physicians' work efficiency, the demand for medical AI products will broaden and accelerate, thereby driving the development of both the medical AI industry and its enterprises.

Taking FUSUN AITROX’s self-developed digital microscopic image analysis system, Aitrox Lens AI, as an example, it comprises an automated microscope scanner and an artificial intelligence analysis module, establishing a one-stop pathological service workflow encompassing “slide scanning, assisted analysis, and structured reporting.” The digital microscopic scanning system of Aitrox Lens AI enables unattended operation, with a single device capable of scanning over 1,000 slides per day. This significantly enhances physicians’ work efficiency (increasing it by 2–3 times compared to traditional manual slide review), helps reduce the probability of misdiagnosis and missed diagnoses, improves diagnostic accuracy, and addresses the shortage of pathologists.

 AITROX PYXIS AI Microscope All-in-One

Mr. Wu Yifang, Chairman of Fosun Pharmastated: “As Fosun Pharma’s first self-incubated AI-assisted medical diagnostic platform, FUSUN AITROX possesses distinct advantages in technological capabilities, business model, and ecosystem integration. This continued investment in FUSUN AITROX underscores Fosun Pharma’s sustained optimism regarding the future development trends of the medical AI industry. Leveraging its technology-driven leadership and integrating healthcare industry resources, Fosun Pharma will collaborate with partners to support and facilitate the rapid growth of FUSUN AITROX.”

Regarding future developments,Mr. Li Ke, General Manager of Sinopharm CICC, the investor in this roundIt stated: “Since its inception, FUSUN AITROX has been positioned as Fosun Group’s strategic initiative in the AI healthcare sector and its sole AI medical imaging platform. Backed by hundreds of millions in funding over several years and supported by medical institutions nationwide under the Fosun Group, it boasts a strong foundation for growth. Sinopharm China International Capital’s shareholder, Sinopharm Group Co., Ltd., is a leading enterprise in China’s pharmaceutical distribution industry, with profound industry expertise and strategic layout. Leveraging shareholder resources, Sinopharm China International Capital will continue to provide capital support and resource integration to foster the development of FUSUN AITROX. Imaging and pathology data form the cornerstone of disease diagnosis, treatment, and health management. In China, where there is a shortage of radiologists and pathologists alongside uneven distribution of medical resources, the application of AI in auxiliary diagnosis for imaging and pathology to enhance efficiency and empower primary-care hospitals is imperative. FUSUN AITROX’s products have been practically validated and well-received across multiple departments and disease types, pioneering the flexible implementation of the SaaS model. We believe that through continuous product innovation and mature commercialization experience, FUSUN AITROX will achieve greater success in serving physicians, patients, and facilitating regional coordination of medical resources.”

AITROX Smart Medical Imaging Cloud + Digital Diagnosis Platform

Gu Qing, Deputy Mayor of the Anting Town People's Government of Jiading District, representing the investor Anting Industrial, stated: “FUSUN AITROX is a key health technology company introduced to Anting Town and serves as an innovative demonstration project for Anting’s digital transformation. It explores the application of artificial intelligence, internet, big data, and cloud platform technologies in medical services and the smart health industry. As the strategic vanguard of Fosun Pharma Group in the field of artificial intelligence, FUSUN AITROX utilizes big data and deep learning to build cross-disciplinary data analysis applications, achieving an upgraded closed-loop management system for the full disease lifecycle. By innovatively integrating medical AI with medical hardware and services, it continuously strengthens R&D breakthroughs in a series of ‘chokepoint’ technologies, realizing domestic substitution. In the future, we will strengthen our cooperation with FUSUN AITROX, accelerate the improvement of the comprehensive health industry system, combine it with the construction of supporting technological industries, vigorously guide the development of the ‘health plus digital economy,’ and foster a thriving health industry across the entire district that serves the whole city and radiates throughout China.”

Leveraging Fosun Pharma’s deep expertise in the broader health and medical sectors, FUSUN AITROX has been strategically positioned as a vanguard of Fosun Pharma’s “innovation-driven” strategy and as a core platform for the medical artificial intelligence industry. It develops cross-disciplinary data analytics applications to further upgrade the closed-loop management of the entire disease lifecycle.

Public information indicates that FUSUN AITROX has become the first medical artificial intelligence enterprise in China to achieve multi-departmental integration across radiology, pathology, ultrasound, cardiology, pulmonology, orthopedics, neurology, and thyroid and breast surgery, attracting multiple key strategic partners both domestically and internationally.

Cardiovascular Imaging Products

In the development of technological and scientific research applications, FUSUN AITROX is dedicated to advancing cross-disciplinary data analytics. The company has secured over 100 patents and achieved multiple championships in international competitions such as LUNA, the Cancer Cellularity Challenge, and MICCAI-FLARE. Furthermore, FUSUN AITROX has been awarded several national-level major projects for innovative initiatives.

Leveraging its technological innovation capabilities, FUSUN AITROX has built a multi-product portfolio. Through its “AI+X” model, it covers multiple diseases and empowers various medical specialties, achieving comprehensive coverage of the entire digital-intelligent healthcare scenario—from clinical diagnosis and treatment plan design to departmental collaboration, remote consultation, and follow-up tracking. This forms an integrated, multi-disease solution spanning from diagnosis to treatment, which can be flexibly combined based on specific needs to assist physicians in their daily clinical practice and support departmental development.

Unique “AI+X” Model Covers All Scenarios of Smart Healthcare

Meanwhile, FUSUN AITROX delves into medical institutions and grassroots health service scenarios to explore actual needs, actively enhancing core service capabilities for tiered diagnosis and treatment—such as early screening, remote consultation, and precision medicine—committed to comprehensively addressing diverse clinical pain points and public health challenges. Through its unique “AI+X” product model, it empowers the construction of remote consultation systems and facilitates the implementation of China’s tiered diagnosis and treatment and precision medicine solutions.

Ms. He Chuan, Global Partner of Fosun and Chairman of FUSUN AITROXHe stated, “We extend our sincere gratitude to both new and existing shareholders, including Fosun Pharma, Sinopharm Zhongjin, and Anting Industrial, for their strong support. With advances in science and technology, public demand for health continues to grow. Beyond basic treatment and diagnosis, chronic disease management and disease prevention have become indispensable components. Medical imaging, particularly AI-powered imaging, as a key means of understanding human organs and capturing health data, has continued to evolve amid this trend. As a domestic artificial intelligence enterprise, FUSUN AITROX has tangibly felt the support provided by the state for the development of the medical AI industry from both regulatory and market perspectives. Looking ahead, FUSUN AITROX will continue to leverage favorable policies, deepen technological R&D, and empower medical research and clinical applications. Through ongoing data accumulation and the construction of robust business models, we aim to serve healthcare institutions and the general public.”

FUSUN AITROX, established in February 2018, is a technology-driven enterprise dedicated to the research and development, production, and sales of AI-powered software and digital solutions for medical imaging and pathology. Its products primarily leverage artificial intelligence to analyze medical images for early disease screening and diagnosis.

FUSUN AITROX is currently the first medical artificial intelligence enterprise in China to achieve multi-department integration across radiology, pathology, ultrasound, cardiology, respiratory medicine, orthopedics, neurology, and thyroid and breast surgery. The company’s multiple products help hospitals address pain points in collaborative applications between medical technology departments and clinical departments, establish patient-centered integrated diagnosis and treatment centers, improve hospital process efficiency and precision therapy, and benefit more patients.

FUSUN AITROX has established industrial collaborations with over 500 renowned medical institutions both domestically and internationally, including Fudan University Shanghai Cancer Center, Zhongshan Hospital Fudan University, Shanghai Sixth People’s Hospital, and Changzheng Hospital of Naval Medical University. It has received widespread recognition, earning awards such as “Top 100 Future Healthcare Companies – Digital Innovation in Healthcare,” “Top Ten AI Healthcare Innovation Projects for Healthy China,” and the China Digital Medicine Smart Service Award. Leveraging a rich industrial ecosystem encompassing medical services, hardware, and consumables, FUSUN AITROX deploys AI products and technologies to further enhance the quality and efficiency of assistance, providing better and more sustainable medical services to people in remote and grassroots areas. This truly realizes AI-driven medical technology services, fulfilling its mission of “Artificial Intelligence Creating Healthy Lives for One Billion Families Worldwide.”

Note:

1. The content of this article is intended solely for academic exchange among professionals.

2. For contraindications or precautions mentioned in this article, please refer to the product instructions for details.